The long term goals of our research are to establish the best pharmacological treatment for NAS and determine how pharmacologic treatment of NAS affects long-term developmental outcomes. The objective of this application is to evaluate the effectiveness of clonidine as a treatment for neonates with NAS, in a randomized clinical trial. Our central hypothesis is that clonidine will effectively treat drug withdrawal manifestations in neonates.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Change in Neurobehavioral Performance Summary Scores From the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS)
Timeframe: Baseline (5-10 days post natal age) and one-month post-natal age (between 4-6 weeks of age), or at discharge, whichever comes first.
Bayley Scales of Infant and Toddler Development Third Edition
Timeframe: 6 months of life
Bayley Scales of Infant and Toddler Development Third Edition
Timeframe: 1 year of life
Bayley Scales of Infant and Toddler Development Third Edition
Timeframe: 2 years of life
Ages and Stages Questionnaire Third Edition (ASQ-3)
Timeframe: 12 months of age
Ages and Stages Questionnaire Third Edition (ASQ-3)
Timeframe: 24 months
Childhood Behavior Checklist (CBCL) T-Scores
Timeframe: Once post discharge (between 18 months up to 24 months of age)